相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
Xin He et al.
BLOOD (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh et al.
NATURE (2019)
Chimeric antigen receptor T cell persistence and memory cell formation
Alexander D. McLellan et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Target selection for CAR-T therapy
Jianshu Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma
Tatsushi Kodama et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
Marijke Timmers et al.
FRONTIERS IN IMMUNOLOGY (2019)
Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma
Ricardo De Matos Simoes et al.
BLOOD (2019)
Recent updates on CAR T clinical trials for multiple myeloma
Quande Lin et al.
MOLECULAR CANCER (2019)
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Deepu Madduri et al.
BLOOD (2019)
Long-Term Follow-up of a Phase 1, Firstin-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Bai-Yan Wang et al.
BLOOD (2019)
Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma
Carlos Fernandez de Larrea et al.
BLOOD (2019)
Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
Jun Wei et al.
NATURE (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
Mattia D'Agostino et al.
CANCERS (2019)
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Andrea Schmidts et al.
BLOOD ADVANCES (2019)
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
Alfonso Quintas-Cardama
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A compound chimeric antigen receptor strategy for targeting multiple myeloma
K. H. Chen et al.
LEUKEMIA (2018)
Chimeric antigen receptor T-cell therapies for lymphoma
Jennifer N. Brudno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Strategies to Address Chimeric Antigen Receptor Tonic Signaling
Adam Ajina et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
Alexander I. Salter et al.
SCIENCE SIGNALING (2018)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Shih-Feng Cho et al.
FRONTIERS IN IMMUNOLOGY (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma
Damian J. Green et al.
BLOOD (2018)
Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies
Nasheed Hossain et al.
BLOOD (2018)
NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells
Alejandra Leivas et al.
BLOOD (2018)
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lydia Lee et al.
BLOOD (2018)
Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma
Cheng Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Potential Therapeutic Targets in Plasma Cell Disorders: A Flow Cytometry Study
Katharina Lisenko et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2017)
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent et al.
MOLECULAR THERAPY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
Dina Schneider et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Tea Gogishvili et al.
BLOOD (2017)
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement
Chen Tian et al.
ANNALS OF HEMATOLOGY (2017)
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
Jae H. Park et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Anti-BCMA CAR T cells show promise in MM
Peter Sidaway
Nature Reviews Clinical Oncology (2016)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Robust isolation of malignant plasma cells in multiple myeloma
Ildiko Frigyesi et al.
BLOOD (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
Monica Casucci et al.
BLOOD (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Evripidis Lanitis et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
Yawara Kawano et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice
JA Westwood et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The RAIG family member, GPRC5D, is associated with hard-keratinized structures
S Inoue et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Systematic determination of the packaging limit of lentiviral vectors
M Kumar et al.
HUMAN GENE THERAPY (2001)
分享论文
